

GILEAD SCIENCES INC
Form 8-K/A
May 08, 2003

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 2)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

May 8, 2003 (January 16, 2003)

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of
incorporation or organization)

0-19731
(Commission File Number)

94-3047598
(I.R.S. Employer Identification
No.)

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)

Edgar Filing: GILEAD SCIENCES INC - Form 8-K/A

94404
(Zip Code)

(650) 574-3000
(Registrant's telephone number, including area code)

This Amended Current Report on Form 8-K amends and supplements the items, financial statements, exhibits and other portions of the Current Report on Form 8-K filed by Gilead Sciences, Inc. with the Commission on January 29, 2003.

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS

(a) On January 16, 2003, Simbolo Acquisition Sub, Inc. (Acquisition Sub), a Delaware corporation and a wholly owned subsidiary of Gilead Sciences, Inc., a Delaware corporation (Gilead), completed a cash tender offer (the Offer) for all of the outstanding common stock of Triangle Pharmaceuticals, Inc. (Triangle) by accepting for payment all shares of Triangle common stock validly tendered and not withdrawn prior to the expiration of the Offer at 12:00 midnight, New York City time, on Wednesday, January 15, 2003. Gilead contributed to Acquisition Sub from cash on hand and cash equivalents the funds necessary to pay for all shares of Triangle common stock accepted for payment by Acquisition Sub in the Offer. On January 16, 2003, Gilead issued a press release, which is filed as Exhibit 99.1 hereto and incorporated by reference herein, announcing the completion of the Offer.

On January 23, 2003, Gilead caused Acquisition Sub to merge with and into Triangle, pursuant to which Triangle became a wholly-owned subsidiary of Gilead, and each share of Triangle common stock not accepted for payment by Acquisition Sub in the Offer was, subject to appraisal rights, converted into the right to receive \$6.00 in cash, without interest. On January 23, 2003, Gilead issued a press release, which is filed as Exhibit 99.2 hereto and incorporated by reference herein, announcing the effectiveness of the merger of Acquisition Sub with and into Triangle.

(b) Gilead is a pharmaceutical company active in the development and commercialization of antiviral drug candidates and Triangle is a pharmaceutical company active in the development of antiviral drug candidates.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(a) Financial statements of businesses acquired

See Exhibit 99.3 for audited financial statements of Triangle.

(b) Pro Forma Financial Information

The unaudited pro forma condensed combined balance sheet as of December 31, 2002 is presented as if Gilead's acquisition of Triangle's net assets had occurred as of that date. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2002 is presented as if Gilead's acquisition of Triangle's net assets had occurred on January 1, 2002.

The Triangle acquisition has been accounted for as an acquisition of assets rather than as a business combination as Triangle is a development stage company that has not commenced its planned principal operations. Triangle lacks the necessary elements of a business because it does not have completed products and, therefore, no ability to access customers.

The pro forma adjustments represent, in the opinion of management, all adjustments necessary to present Gilead's pro forma results of operations and financial position in accordance with Article 11 of SEC Regulation S-X and are based upon available information and certain assumptions considered reasonable under the circumstances. The purchase price has been allocated to the acquired assets and liabilities based on a preliminary determination of their respective fair values.

The pro forma information may not necessarily be indicative of Gilead's results of operations or financial position had the transaction been in effect as of or for the periods presented, nor is such information necessarily indicative of Gilead's results of operations or financial position for any future period or date. Furthermore, no effect has been given in the unaudited pro forma condensed combined statement of operations for synergies that may be realized through the combination of Gilead and Triangle or costs that may be incurred in integrating their operations. The unaudited pro forma condensed combined financial statements should be read in conjunction with Gilead's audited consolidated financial statements and notes thereto included in Gilead's amended annual report on Form 10-K/A for the year ended December 31, 2002 and the historical consolidated financial statements, including the notes thereto, of Triangle, included as Exhibit 99.3 to Gilead's Amended Current Report on Form 8-K/A filed with the SEC on March 13, 2003.

GILEAD SCIENCES, INC.

PRO FORMA CONDENSED COMBINED BALANCE SHEET

(unaudited)

(in thousands, except per share amounts)

| | December 31, 2002 | | | | | |
|--|-----------------------|-----------------------------------|--------------------------|---|------------|--|
| | Gilead Sciences, Inc. | Triangle Pharmaceuticals, Inc. | Pro forma adjustments | | Pro forma | |
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | \$ 616,931 | \$ 65,469 | \$ (463,147) | A | \$ 219,253 | |
| Marketable securities | 325,443 | 33,733 | | | 359,176 | |
| Accounts receivable | 125,036 | | | | 125,036 | |
| Note receivable from Triangle | 50,000 | | (50,000) | B | | |
| Inventories | 51,628 | | | | 51,628 | |
| Prepaid expenses and other | 14,722 | 1,361 | | | 16,083 | |
| Total current assets | 1,183,760 | 100,563 | (513,147) | | 771,176 | |
| Property, plant and equipment, net | | | | | | |
| | 67,727 | 2,792 | | | 70,519 | |
| Other noncurrent assets | 36,696 | 1,000 | 4,600 | C | 42,296 | |
| | \$ 1,288,183 | \$ 104,355 | \$ (508,547) | | \$ 883,991 | |
| Liabilities and stockholders equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | \$ 24,406 | \$ 6,245 | \$ | | \$ 30,651 | |
| Accrued clinical and preclinical expenses | 7,063 | 10,640 | | | 17,703 | |
| Accrued compensation and employee benefits | 21,511 | 1,116 | 6,612 | D | 29,239 | |
| Other accrued liabilities | 44,026 | 3,072 | 13,599 | E | 63,953 | |
| | | | 3,256 | C | | |
| Deferred revenue | 7,692 | | | | 7,692 | |
| Long-term obligations due within one year | 194 | 1,801 | | | 1,995 | |
| Total current liabilities | 104,892 | 22,874 | 23,467 | | 151,233 | |
| Long-term deferred revenue | 16,677 | 2,000 | (2,000) | C | 16,677 | |
| Long-term obligations due after one year | 273 | 50,008 | (50,000) | B | 281 | |
| Convertible senior debt | 345,000 | | | | 345,000 | |
| Convertible subordinated debt | 250,000 | | | | 250,000 | |
| Commitments and contingencies | | | | | | |
| Stockholders equity: | | | | | | |
| | 198 | 77 | (77) | F | 198 | |

Edgar Filing: GILEAD SCIENCES INC - Form 8-K/A

| | | | | | |
|--|--------------|------------|--------------|---|------------|
| Common stock, par value \$.001 per share; 500,000 shares authorized; 197,595 shares issued and outstanding | | | | | |
| Additional paid-in capital | 950,308 | 470,855 | (470,855) | F | 991,647 |
| | | | 41,339 | G | |
| Deferred compensation | | | (3,823) | G | (3,823) |
| Accumulated other comprehensive income | 2,475 | 96 | (96) | F | 2,475 |
| Accumulated deficit | (381,640) | (441,555) | 441,555 | F | (869,697) |
| | | | (488,057) | H | |
| Total stockholders' equity | 571,341 | 29,473 | (480,014) | | 120,800 |
| | \$ 1,288,183 | \$ 104,355 | \$ (508,547) | | \$ 883,991 |

See notes to pro forma condensed combined financial statements.

GILEAD SCIENCES, INC.

PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

| | Year ended December 31, 2002 | | | | |
|---|------------------------------|-----------------------------------|--------------------------|---|------------|
| | Gilead Sciences, Inc. | Triangle Pharmaceuticals, Inc. | Pro forma adjustments | | Pro forma |
| Revenues: | | | | | |
| Product sales, net | \$ 423,879 | \$ | \$ | | \$ 423,879 |
| Royalty revenue, net | 20,406 | | | | 20,406 |
| Contract revenue | 22,505 | 16,625 | | | 39,130 |
| Total revenues | 466,790 | 16,625 | | | 483,415 |
| Costs and expenses: | | | | | |
| Cost of goods sold | 69,724 | | | | 69,724 |
| Research and development | 134,758 | 54,683 | 1,000 | I | 190,441 |
| Selling, general and administrative | 181,301 | 8,411 | 1,758 | I | 191,470 |
| Total costs and expenses | 385,783 | 63,094 | 2,758 | | 451,635 |
| Income (loss) from operations | 81,007 | (46,469) | (2,758) | | 31,780 |
| Gain (loss) on sale of marketable securities | (16,048) | 14 | | | (16,034) |
| Insurance proceeds | | 10,000 | | | 10,000 |
| Interest income | 22,291 | 2,275 | (8,471) | J | 16,095 |
| Interest expense | (13,853) | (480) | | | (14,333) |
| Income (loss) before provision for income taxes | 73,397 | (34,660) | (11,229) | | 27,508 |
| Provision for income taxes | 1,300 | | | | 1,300 |
| Net income (loss) | \$ 72,097 | \$ (34,660) | \$ (11,229) | | \$ 26,208 |
| Basic and diluted net loss per common share: | | | | | |
| Earnings per share basic | \$ 0.37 | | | | \$ 0.13 |
| Earnings per share diluted | \$ 0.35 | | | | \$ 0.13 |
| Shares used in per share calculation basic | 195,543 | | | | 195,543 |
| Shares used in per share calculation diluted | 206,477 | | | | 206,477 |

See notes to pro forma condensed combined financial statements.

NOTES TO PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Basis of Presentation

On January 16, 2003, Acquisition Sub completed the Offer for all of the outstanding common stock of Triangle Pharmaceuticals, Inc. (Triangle) by accepting for payment all shares of Triangle common stock validly tendered and not withdrawn prior to the expiration of the Offer at 12:00 midnight, New York City time, on Wednesday, January 15, 2003. Gilead contributed to Acquisition Sub from cash on hand and cash equivalents the funds necessary to pay for all shares of Triangle common stock accepted for payment by Acquisition Sub in the Offer.

On January 23, 2003, Gilead caused Acquisition Sub to merge with and into Triangle, pursuant to which Triangle became a wholly-owned subsidiary of Gilead, and each share of Triangle common stock not accepted for payment by Acquisition Sub in the Offer was, subject to appraisal rights, converted into the right to receive \$6.00 in cash, without interest.

The Triangle acquisition has been accounted for as an acquisition of assets rather than as a business combination as Triangle is a development stage company that has not commenced its planned principal operations. Triangle lacks the necessary elements of a business because it does not have completed products and, therefore, no ability to access customers.

The unaudited pro forma condensed combined financial statements present financial information for Gilead giving effect to the acquisition of the net assets of Triangle. The unaudited pro forma condensed combined balance sheet as of December 31, 2002 is presented as if the acquisition occurred on that date. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2002 is presented as if the acquisition had occurred on January 1, 2002.

For purposes of the unaudited pro forma condensed combined financial statements, Gilead assumed an aggregate preliminary purchase price of \$525 million, including cash paid to the Triangle stockholders of \$463 million, the fair value of stock options assumed of \$41 million, estimated transaction costs of \$14 million and estimated employee termination costs of \$7 million. The unaudited pro forma condensed combined financial statements reflect adjustments that are based upon preliminary estimates of the allocation of the purchase price to the acquired assets and liabilities of Triangle based on available information and certain assumptions that Gilead believes are reasonable in the circumstances.

Gilead anticipates a significant portion of the purchase price (currently estimated to be \$488 million) to be allocated to in-process research and development due to Triangle's incomplete research and development programs that had not yet reached technological feasibility and had no alternative future use as of that date. A summary of these programs follows:

| <u>Program</u> | <u>Description</u> | <u>Status of Development at Acquisition Date</u> | <u>Value Assigned (\$ in millions)</u> |
|---|--|--|--|
| Emtricitabine for HIV - Single Agent | A nucleoside analogue that has been shown to be an inhibitor of HIV and hepatitis B virus (HBV) replication in laboratory studies. | Four phase 3 studies completed; application for marketing approval submitted in the U.S. in September 2002 and in the European Union in December 2002 | \$179 |
| Emtricitabine for HIV - Combination Therapy | A potential co-formulation of Viread and emtricitabine; dependent upon successful marketing approval of emtricitabine as a single agent. | Preclinical stage - formulation work is beginning. As of the acquisition date, work had not yet commenced on the potential co-formulation except to the extent that work on emtricitabine as a single agent was progressing. | \$106 |
| Amdoxovir for HIV | A purine dioxolane nucleoside that may offer advantages over other marketed nucleosides because of its activity against drug resistant viruses as exhibited in laboratory studies. | Two phase 2 trials initiated; currently placed on partial hold. | \$115 |
| Clevudine for HBV | A pyrimidine nucleoside analogue that has been shown to be an inhibitor of HBV replication in laboratory studies. | Phase 1/2 trials | \$ 59 |
| Emtricitabine for HBV | An inhibitor of HBV replication in patients chronically infected with HBV. | Phase 3 trial ongoing | \$ 29 |

The nature of the remaining efforts for completion primarily consist of ongoing clinical trials and studies, the cost, length and success of which are extremely difficult to determine. Numerous risks and uncertainties exist with timely completion of development, including the uncertainty and timing of patient enrollment and uncertainties related to the results of the studies, including interpretation of the data and obtaining FDA and other regulatory body approvals. Feedback from regulatory authorities or results from clinical studies might require modifications or delays in later stage clinical trials or additional studies to be performed. Specifically with regard to emtricitabine for HIV as a single agent, we cannot be certain that this potential product will be approved in the U.S. or the European Union or whether marketing approvals will have significant limitations on its use. For example, regulatory agencies may not approve emtricitabine for treatment of HIV if it is determined that the potential product does not have sufficient efficacy advantages over a currently marketed lamivudine product. The acquired products under development may never be successfully commercialized due to the uncertainties associated with the pricing of new pharmaceuticals and the fact that the cost of sales to produce these products in a commercial setting has not been determined. If these programs can not be completed on a timely basis, then our prospects for future revenue growth would be adversely impacted.

The preliminary value of the acquired in-process research and development was determined by estimating the related future net cash flows using a present value discount rate of 15.75%. This discount rate is a significant assumption and is based on Gilead's estimated weighted average cost of capital taking into account the risks associated with the projects acquired. The projected cash flows from such projects were based on estimates of revenues and operating profits related to such projects considering, the stage of development of each potential product acquired, the time and resources needed to complete each product, the estimated life of each potential commercialized product and associated risks including the inherent difficulties and uncertainties in developing a drug compound including obtaining FDA and other regulatory approvals, and risks related to the viability of and potential alternative treatments in any future target markets. In determining the value of the in-process research and development, the assumed commercialization dates for these potential products ranged from 2003 to 2020.

The final allocation of the purchase price, which may be different from the current estimate, will be based upon an appraisal prepared by an independent third party and a comprehensive evaluation of the fair value of the acquired intangible and tangible assets and liabilities, including in-process research and development and liabilities assumed as of the closing date. The final determination of tangible and intangible assets purchased may result in future depreciation and amortization expenses that are different from the preliminary estimates of these amounts. As a result of these uncertainties, the exact amount of the final purchase price and allocation of such purchase price may differ from the amounts assumed in the unaudited pro forma condensed combined financial statements.

This charge for in-process research and development will be recorded as of the acquisition date and included in Gilead's statement of operations for the quarter ending March 31, 2003.

Unaudited Pro Forma Adjustments

Pro Forma Condensed Combined Balance Sheet

- A) Reflects the cash payment for 77,191,227 shares of Triangle common stock.

- B) Reflects the elimination of a note executed in December 2002 between Gilead and Triangle.

- C) Adjustments to the historical amounts of Triangle's net assets to reflect the estimated fair values of identifiable tangible and intangible assets and liabilities of Triangle acquired. The \$4.6 million of intangible assets acquired relate to Triangle's assembled workforce which will be amortized over 3 years, the estimated useful life of these assets.

- D) Reflects accrued compensation and employee benefits related to estimated employee termination costs which have been included as part of the purchase consideration.

- E) Reflects the estimated liability for costs and expenses directly related to this transaction, including investment banking, legal and accounting fees which have been included as part of the purchase consideration.

- F) Reflects the elimination of Triangle's stockholders' equity accounts.

- G) Reflects the estimated fair value of options assumed of \$41 million and the estimated intrinsic value of assumed unvested stock options of \$4 million which has been recorded as deferred compensation.

- H) Reflects the estimated in-process research and development charge of \$488 million related to the acquisition. This in-process research and development charge is reflected in the unaudited pro forma condensed combined balance sheet, but is not reflected in the unaudited pro forma condensed combined statement of operations included herein since it is a nonrecurring charge directly attributable to the transaction. The in-process research and development charge will be reflected as an expense in Gilead's statement of operations for the quarter ending March 31, 2003.

Pro Forma Condensed Combined Statement of Operations

I) Reflects the amortization of \$1.5 million of acquired intangible assets based on the estimated fair value and estimated useful life assigned to these assets at the date of acquisition and the amortization of deferred compensation of \$1.2 million related to the unvested stock options assumed in the acquisition.

J) Reflects a decrease in interest income due to the cash element of the purchase consideration presumed to have been paid at the beginning of the year.

(c) Exhibits

| Exhibit Number | Description |
|----------------|--|
| 23.1 | Consent of PricewaterhouseCoopers LLP |
| 99.1 | Press Release, issued by Gilead Sciences, Inc. on January 16, 2003 (1) |
| 99.2 | Press Release, issued by Gilead Sciences, Inc. on January 23, 2003 (2) |
| 99.3 | Financial statements of Triangle Pharmaceuticals, Inc. (3) |
| 99.4 | Certification |

(1) Filed as Exhibit 99.1 to Current Report on Form 8-K filed by Gilead Sciences, Inc. with the Commission on January 29, 2003

(2) Filed as Exhibit 99.2 to Current Report on Form 8-K filed by Gilead Sciences, Inc. with the Commission on January 29, 2003

(3) Previously Filed as Exhibit 99.3 to Amended Current Report on Form 8-K/A filed by Gilead Sciences, Inc. with the Commission on March 13, 2003 and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned hereunto duly authorized.

| |
|--|
| GILEAD SCIENCES, INC. |
| (registrant) |
| |
| /s/John F. Milligan |
| John F. Milligan |
| Senior Vice President and Chief Financial Officer |

Date: May 7, 2003

Exhibits

| Exhibit Number | Description |
|----------------|--|
| 23.1 | Consent of PricewaterhouseCoopers LLP |
| 99.1 | Press Release, issued by Gilead Sciences, Inc. on January 16, 2003 (1) |
| 99.2 | Press Release, issued by Gilead Sciences, Inc. on January 23, 2003 (2) |
| 99.3 | Financial statements of Triangle Pharmaceuticals, Inc. (3) |
| 99.4 | Certification |

(1) Filed as Exhibit 99.1 to Current Report on Form 8-K filed by Gilead Sciences, Inc. with the Commission on January 29, 2003

(2) Filed as Exhibit 99.2 to Current Report on Form 8-K filed by Gilead Sciences, Inc. with the Commission on January 29, 2003

(3) Previously Filed as Exhibit 99.3 to Amended Current Report on Form 8-K/A filed by Gilead Sciences, Inc. with the Commission on March 13, 2003 and incorporated herein by reference.